Clinical Research Directory
Browse clinical research sites, groups, and studies.
Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant
Sponsor: Columbia University
Summary
The purpose of this study is to compare the safety and efficacy of letermovir with valganciclovir for prevention of Cytomegalovirus (CMV) viremia in moderate to high risk serostatus heart transplant recipients.
Official title: VALganciclovir vs. LETermovir for Primary Prevention of CMV in Moderate to High-Risk Heart Transplant Recipients (The VALET-CMV Study)
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2025-09-12
Completion Date
2029-01-17
Last Updated
2025-09-25
Healthy Volunteers
No
Interventions
Letermovir
CMV prophylaxis
Valganciclovir
Standard therapy for CMV prophylaxis
Locations (2)
NYP-Weill Cornell
New York, New York, United States
Columbia University/NYP Milstein Hospital
New York, New York, United States